Palisade Bio, Inc. (PALI): Operating Cash Flow
-$10.85M
Year ended 2025-12-31
-$18.19M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$10.85M | n/m | 2026-03-20, From 2025-01-01 |
| 2024-12-31 | -$12.19M | n/m | 2026-03-20, From 2024-01-01 |
| 2023-12-31 | -$11.13M | n/m | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | -$13.36M | n/m | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | -$14.77M | n/m | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | -$4.77M | n/c | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | -$7.26M | n/m | 2021-03-22, From 2019-01-01 |
| 2018-12-31 | -$7.69M | n/m | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | -$13.42M | n/m | 2019-03-22, From 2017-01-01 |
| 2016-12-31 | -$15.62M | n/m | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | -$18.93M | n/m | 2017-03-23, From 2015-01-01 |
| 2014-12-31 | -$11.71M | n/m | 2016-03-14, From 2014-01-01 |
| 2013-12-31 | -$10.59M | n/m | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | -$8.48M | n/m | 2013-03-15, From 2012-01-01 |
| 2011-12-31 | -$8.10M | n/m | 2013-03-15, From 2011-01-01 |
| 2010-12-31 | -$9.98M | n/m | 2012-03-30, From 2010-01-01 |
| 2009-12-31 | -$5.14M | n/a | 2012-03-30, From 2009-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Palisade Bio, Inc. (PALI) | 2025-12-31 | -$10.85M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $7.71M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $9.96B | -13.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $117.42M | -33.1% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$4.47M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $292.07M | +1.6% |
| Biogen Inc. (BIIB) | 2025-12-31 | $2.20B | -23.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$18.92M | n/m |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $10.02B | -7.5% |
Compare PALI, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗